Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Amgen Inc.

NASDAQ

Market Cap.

164.06B

Avg. Volume

2.73M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Amgen Inc.!

Still processing it, give me a bit more time...

Amgen Inc. News

Amgen Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
amgen.com

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. Earnings & Revenue

Amgen Inc. Financials

Table Compare

Compare AMGN metrics with:

   

Earnings & Growth

AMGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

AMGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

AMGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

AMGN

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Amgen Inc. Income

Amgen Inc. Balance Sheet

Amgen Inc. Cash Flow

Amgen Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquitySell
Return on AssetsNeutral
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Amgen Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

8.7600

Payment DateDividendFrequency
2024-06-072.25Quarterly
2024-03-072.25Quarterly
2023-12-082.13Quarterly
2023-09-082.13Quarterly
2023-06-082.13Quarterly

Historical Market Cap

Shares Outstanding

Amgen Inc. Executives

NameRole
Mr. Robert A. BradwayChairman, Chief Executive Officer & President
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations
Mr. Peter H. GriffithExecutive Vice President & Chief Financial Officer
Mr. Esteban SantosExecutive Vice President of Operations
NameRoleGenderDate of BirthPay
Mr. Robert A. BradwayChairman, Chief Executive Officer & PresidentMale19636.73M
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer19633.4M
Mr. Murdo GordonExecutive Vice President of Global Commercial OperationsMale19673.24M
Mr. Peter H. GriffithExecutive Vice President & Chief Financial OfficerMale19593.07M
Mr. Esteban SantosExecutive Vice President of OperationsMale19683.01M

Amgen Inc. Insider Trades

Date7 May
NameSantos Esteban
RoleEVP, Operations
TransactionAcquired
TypeA-Award
Shares2997
Date7 May
NameSantos Esteban
RoleEVP, Operations
TransactionAcquired
TypeA-Award
Shares19469
Date7 May
NameREESE DAVID M
RoleEVP & Chief Technology Officer
TransactionAcquired
TypeA-Award
Shares3196
Date7 May
NameREESE DAVID M
RoleEVP & Chief Technology Officer
TransactionAcquired
TypeA-Award
Shares20767
Date7 May
NameMiller Derek
RoleSVP, Human Resources
TransactionAcquired
TypeA-Award
Shares865
DateNameRoleTransactionTypeShares
7 MaySantos EstebanEVP, OperationsAcquiredA-Award2997
7 MaySantos EstebanEVP, OperationsAcquiredA-Award19469
7 MayREESE DAVID MEVP & Chief Technology OfficerAcquiredA-Award3196
7 MayREESE DAVID MEVP & Chief Technology OfficerAcquiredA-Award20767
7 MayMiller DerekSVP, Human ResourcesAcquiredA-Award865

Discover More

Streamlined Academy

Amgen Inc.

NASDAQ

Market Cap.

164.06B

Avg. Volume

2.73M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Amgen Inc. News

Amgen Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Amgen Inc. Earnings & Revenue

Amgen Inc. Income

Amgen Inc. Balance Sheet

Amgen Inc. Cash Flow

Amgen Inc. Financials Over Time

Amgen Inc. Executives

NameRole
Mr. Robert A. BradwayChairman, Chief Executive Officer & President
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations
Mr. Peter H. GriffithExecutive Vice President & Chief Financial Officer
Mr. Esteban SantosExecutive Vice President of Operations
NameRoleGenderDate of BirthPay
Mr. Robert A. BradwayChairman, Chief Executive Officer & PresidentMale19636.73M
Dr. David M. Reese M.D.Executive Vice President & Chief Technology Officer19633.4M
Mr. Murdo GordonExecutive Vice President of Global Commercial OperationsMale19673.24M
Mr. Peter H. GriffithExecutive Vice President & Chief Financial OfficerMale19593.07M
Mr. Esteban SantosExecutive Vice President of OperationsMale19683.01M

Amgen Inc. Insider Trades

Date7 May
NameSantos Esteban
RoleEVP, Operations
TransactionAcquired
TypeA-Award
Shares2997
Date7 May
NameSantos Esteban
RoleEVP, Operations
TransactionAcquired
TypeA-Award
Shares19469
Date7 May
NameREESE DAVID M
RoleEVP & Chief Technology Officer
TransactionAcquired
TypeA-Award
Shares3196
Date7 May
NameREESE DAVID M
RoleEVP & Chief Technology Officer
TransactionAcquired
TypeA-Award
Shares20767
Date7 May
NameMiller Derek
RoleSVP, Human Resources
TransactionAcquired
TypeA-Award
Shares865
DateNameRoleTransactionTypeShares
7 MaySantos EstebanEVP, OperationsAcquiredA-Award2997
7 MaySantos EstebanEVP, OperationsAcquiredA-Award19469
7 MayREESE DAVID MEVP & Chief Technology OfficerAcquiredA-Award3196
7 MayREESE DAVID MEVP & Chief Technology OfficerAcquiredA-Award20767
7 MayMiller DerekSVP, Human ResourcesAcquiredA-Award865

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
amgen.com

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Amgen Inc.!

Still processing it, give me a bit more time...

Amgen Inc. Financials

Table Compare

Compare AMGN metrics with:

   

Earnings & Growth

AMGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

AMGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

AMGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

AMGN

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Amgen Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

8.7600

Payment DateDividendFrequency
2024-06-072.25Quarterly
2024-03-072.25Quarterly
2023-12-082.13Quarterly
2023-09-082.13Quarterly
2023-06-082.13Quarterly

Amgen Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquitySell
Return on AssetsNeutral
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More